{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:06:18Z","timestamp":1784977578357,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01657-3","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T08:08:40Z","timestamp":1746000520000},"page":"761-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Swati","family":"Popli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri M.","family":"Durant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"1","key":"1657_CR1","doi-asserted-by":"publisher","first-page":"7543","DOI":"10.1038\/s41598-018-26002-6","volume":"8","author":"P Ge","year":"2018","unstructured":"Ge P, Wang L, Lu M, Mao L, Li W, Wen R, et al. Oncological outcome of primary and secondary Muscle-Invasive bladder cancer: A systematic review and Meta-analysis. Sci Rep. 2018;8(1):7543. https:\/\/doi.org\/10.1038\/s41598-018-26002-6.","journal-title":"Sci Rep"},{"issue":"12","key":"1657_CR2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.ejso.2014.10.004","volume":"40","author":"J Schiffmann","year":"2014","unstructured":"Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, Shariat SF, et al. Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol (EJSO). 2014;40(12):1738\u201345. https:\/\/doi.org\/10.1016\/j.ejso.2014.10.004.","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"10139","key":"1657_CR3","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","volume":"391","author":"DJ Parekh","year":"2018","unstructured":"Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018;391(10139):2525\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(18)30996-6.","journal-title":"Lancet"},{"issue":"13","key":"1657_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa2401497","volume":"391","author":"SP Lerner","year":"2024","unstructured":"Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, et al. Standard or extended lymphadenectomy for Muscle-Invasive bladder Cancer. N Engl J Med. 2024;391(13):1206\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2401497.","journal-title":"N Engl J Med"},{"issue":"6suppl","key":"1657_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2021.39.6_suppl.424","volume":"39","author":"NM Hahn","year":"2021","unstructured":"Hahn NM, Sachse K, Schulman D, Sloan F, Quale DZ, Lotan Y, et al. Patient, caregiver, and provider reported risk-benefit acceptance thresholds in non-muscle invasive bladder cancer (NMIBC) trial designs. J Clin Oncol. 2021;39(6suppl):424. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.424.","journal-title":"J Clin Oncol"},{"issue":"6 Suppl 4","key":"1657_CR6","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.5489\/cuaj.1196","volume":"3","author":"AR Zlotta","year":"2009","unstructured":"Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J. 2009;3(6 Suppl 4):S199\u2013205. https:\/\/doi.org\/10.5489\/cuaj.1196.","journal-title":"Can Urol Assoc J"},{"issue":"5","key":"1657_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","volume":"49","author":"JA Witjes","year":"2006","unstructured":"Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49(5):790\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2006.01.017.","journal-title":"Eur Urol"},{"issue":"1","key":"1657_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158(1):62\u20137. https:\/\/doi.org\/10.1097\/00005392-199707000-00017.","journal-title":"J Urol"},{"issue":"15","key":"1657_CR9","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMp1615697","volume":"376","author":"BJ Davies","year":"2017","unstructured":"Davies BJ, Hwang TJ, Kesselheim AS. Ensuring access to injectable generic Drugs - The case of intravesical BCG for bladder Cancer. N Engl J Med. 2017;376(15):1401\u20133. https:\/\/doi.org\/10.1056\/NEJMp1615697.","journal-title":"N Engl J Med"},{"issue":"3","key":"1657_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bju.15661","volume":"130","author":"N Lobo","year":"2022","unstructured":"Lobo N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, Abraham P, Navai N, et al. Reduced-dose bacillus Calmette-Gu\u00e9rin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre. BJU Int. 2022;130(3):323\u201330. https:\/\/doi.org\/10.1111\/bju.15661.","journal-title":"BJU Int"},{"issue":"3","key":"1657_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of Valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin study group. J Urol. 2000;163(3):761\u20137.","journal-title":"J Urol"},{"issue":"2","key":"1657_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","volume":"83","author":"JP Jarow","year":"2014","unstructured":"Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a food and drug administration and American urological association public workshop. Urology. 2014;83(2):262\u20134. https:\/\/doi.org\/10.1016\/j.urology.2013.10.030.","journal-title":"Urology"},{"issue":"16","key":"1657_CR13","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/jco.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, B\u00f6hle A, Palou J, Lamm DL, Brausi M, et al. Definitions, end points, and clinical trial designs for Non-Muscle-Invasive bladder cancer: recommendations from the international bladder Cancer group. J Clin Oncol. 2016;34(16):1935\u201344. https:\/\/doi.org\/10.1200\/jco.2015.64.4070.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1657_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(21)00147-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1657_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","volume":"10","author":"WF Benedict","year":"2004","unstructured":"Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004;10(3):525\u201332. https:\/\/doi.org\/10.1016\/j.ymthe.2004.05.027.","journal-title":"Mol Ther"},{"issue":"1","key":"1657_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene Firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107\u201317. https:\/\/doi.org\/10.1016\/s1470-2045(20)30540-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1657_CR17","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie K, Chang SS, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, et al. IL-15 superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive bladder Cancer. NEJM Evid. 2023;2(1):EVIDoa2200167. https:\/\/doi.org\/10.1056\/EVIDoa2200167.","journal-title":"NEJM Evid"},{"issue":"1","key":"1657_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.Ccr-05-1059","volume":"12","author":"N Ramesh","year":"2006","unstructured":"Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, et al. CG0070, a conditionally replicating granulocyte macrophage Colony-Stimulating Factor\u2013Armed oncolytic adenovirus for the treatment of bladder Cancer. Clin Cancer Res. 2006;12(1):305\u201313. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-1059.","journal-title":"Clin Cancer Res"},{"key":"1657_CR19","doi-asserted-by":"crossref","unstructured":"Tyson MDUE, Nam JK, Lamm DL, Bivalacqua TJ, Shore ND. Single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk. A Phase 3, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Journal of Urology [Internet]. 2024(211).","DOI":"10.1097\/01.JU.0001015816.87470.c9.02"},{"issue":"1","key":"1657_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","volume":"172","author":"GN Thalmann","year":"2004","unstructured":"Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol. 2004;172(1):70\u20135. https:\/\/doi.org\/10.1097\/01.ju.0000132129.87598.3b.","journal-title":"J Urol"},{"issue":"3","key":"1657_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031. discussion 75\u2013\u20097.","journal-title":"Eur Urol"},{"issue":"34","key":"1657_CR22","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/jco.23.02510","volume":"42","author":"DM Dahl","year":"2024","unstructured":"Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, et al. Bladder-Preserving trimodality treatment for High-Grade T1 bladder cancer: results from phase II protocol NRG oncology\/rtog 0926. J Clin Oncol. 2024;42(34):4095\u2013102. https:\/\/doi.org\/10.1200\/jco.23.02510.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1657_CR23","doi-asserted-by":"publisher","first-page":"38378","DOI":"10.18632\/oncotarget.16386","volume":"8","author":"G Yang","year":"2017","unstructured":"Yang G, Shen W, Zhang Y, Liu M, Zhang L, Liu Q, et al. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017;8(24):38378\u201388. https:\/\/doi.org\/10.18632\/oncotarget.16386.","journal-title":"Oncotarget"},{"issue":"3","key":"1657_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","volume":"81","author":"MB Clements","year":"2022","unstructured":"Clements MB, Atkinson TM, Dalbagni GM, Li Y, Vickers AJ, Herr HW, et al. Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort. Eur Urol. 2022;81(3):294\u2013304. https:\/\/doi.org\/10.1016\/j.eururo.2021.09.018.","journal-title":"Eur Urol"},{"issue":"1","key":"1657_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1464-410X.2012.11762.x","volume":"112","author":"ZL Smith","year":"2013","unstructured":"Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013;112(1):13\u201325. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11762.x.","journal-title":"BJU Int"},{"key":"1657_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.020","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term outcomes after bladder-preserving Tri-modality therapy for patients with Muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience. Eur Urol. 2017. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.020.","journal-title":"Eur Urol"},{"issue":"4","key":"1657_CR27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","volume":"73","author":"DS Kaufman","year":"2009","unstructured":"Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, et al. Phase I-II RTOG study (99\u2013\u200906) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, Paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833\u20137. https:\/\/doi.org\/10.1016\/j.urology.2008.09.036.","journal-title":"Urology"},{"issue":"16","key":"1657_CR28","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477\u201388. https:\/\/doi.org\/10.1056\/NEJMoa1106106.","journal-title":"N Engl J Med"},{"issue":"4","key":"1657_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, et al. NCCN guidelines\u00ae insights: bladder cancer, version 3.2024: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2024;22(4):216\u201325. https:\/\/doi.org\/10.6004\/jnccn.2024.0024.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"1657_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of Non-Metastatic Muscle-Invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol. 2017;198(3):552\u20139. https:\/\/doi.org\/10.1016\/j.juro.2017.04.086.","journal-title":"J Urol"},{"issue":"1","key":"1657_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85(1):17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016.","journal-title":"Eur Urol"},{"issue":"2","key":"1657_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ijrobp.2013.01.020","volume":"86","author":"JJ Coen","year":"2013","unstructured":"Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, et al. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013;86(2):311\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.01.020.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1657_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/0360-3016(93)90306-g","volume":"25","author":"W Tester","year":"1993","unstructured":"Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85\u2013\u200912. Int J Radiat Oncol Biol Phys. 1993;25(5):783\u201390. https:\/\/doi.org\/10.1016\/0360-3016(93)90306-g.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1657_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/jco.1996.14.1.119","volume":"14","author":"W Tester","year":"1996","unstructured":"Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of radiation therapy oncology group phase II trial 8802. J Clin Oncol. 1996;14(1):119\u201326. https:\/\/doi.org\/10.1200\/jco.1996.14.1.119.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1657_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"DS Kaufman","year":"2000","unstructured":"Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, et al. The initial results in muscle-invading bladder cancer of RTOG 95\u2013\u200906: phase I\/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5(6):471\u20136. https:\/\/doi.org\/10.1634\/theoncologist.5-6-471.","journal-title":"Oncologist"},{"issue":"11","key":"1657_CR36","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","volume":"16","author":"WU Shipley","year":"1998","unstructured":"Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89\u2013\u200903. J Clin Oncol. 1998;16(11):3576\u201383. https:\/\/doi.org\/10.1200\/JCO.1998.16.11.3576.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1657_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/jco.18.00537","volume":"37","author":"JJ Coen","year":"2019","unstructured":"Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, et al. Bladder preservation with Twice-a-Day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for Muscle-Invasive bladder cancer: NRG\/RTOG 0712-A randomized phase II trial. J Clin Oncol. 2019;37(1):44\u201351. https:\/\/doi.org\/10.1200\/jco.18.00537.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1657_CR38","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/jco.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171\u20137. https:\/\/doi.org\/10.1200\/jco.2010.32.3139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1657_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/blc-240036","volume":"10","author":"P Singh","year":"2024","unstructured":"Singh P, Ballas L, Sonpavde GP, Chen RC, Bangs R, Bauman BC, et al. Eligibility and endpoints for clinical trials in trimodality therapy for bladder Cancer. Bladder Cancer. 2024;10(3):199\u2013213. https:\/\/doi.org\/10.3233\/blc-240036.","journal-title":"Bladder Cancer"},{"issue":"5","key":"1657_CR40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","volume":"110","author":"YP Song","year":"2021","unstructured":"Song YP, Mistry H, Irlam J, Valentine H, Yang L, Lane B, et al. Long-Term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-Year update of the BCON (Bladder carbogen Nicotinamide) phase 3 randomized trial (ISRCTN45938399). Int J Radiat Oncol Biol Phys. 2021;110(5):1407\u201315. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.001.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1657_CR41","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","volume":"101","author":"AC Tree","year":"2018","unstructured":"Tree AC, Jones K, Hafeez S, Sharabiani MTA, Harrington KJ, Lalondrelle S, et al. Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder Cancer. Int J Radiat Oncol Biol Phys. 2018;101(5):1168\u201371. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.04.070.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1657_CR42","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","volume":"57","author":"MP Hagan","year":"2003","unstructured":"Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, et al. RTOG 97\u2013\u200906: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(3):665\u201372.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1657_CR43","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","volume":"80","author":"A Zapatero","year":"2012","unstructured":"Zapatero A, Martin De Vidales C, Arellano R, Iba\u00f1ez Y, Bocardo G, Perez M, et al. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology. 2012;80(5):1056\u201362. https:\/\/doi.org\/10.1016\/j.urology.2012.07.045.","journal-title":"Urology"},{"issue":"14","key":"1657_CR44","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after chemoradiotherapy in Limited-Stage Small-Cell lung Cancer. N Engl J Med. 2024;391(14):1313\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2404873.","journal-title":"N Engl J Med"},{"issue":"3","key":"1657_CR45","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.euo.2023.09.011","volume":"7","author":"A Weickhardt","year":"2024","unstructured":"Weickhardt A, Foroudi F, Lawrentschuk N, Xie J, Sidhom M, Pal A, et al. Pembrolizumab with chemoradiation as treatment for Muscle-invasive bladder cancer: analysis of safety and efficacy of the PCR-MIB phase 2 clinical trial (ANZUP 1502). Eur Urol Oncol. 2024;7(3):469\u201377. https:\/\/doi.org\/10.1016\/j.euo.2023.09.011.","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"1657_CR46","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.juro.2014.03.078","volume":"192","author":"A Meyer","year":"2014","unstructured":"Meyer A, Ghandour R, Bergman A, Castaneda C, Wosnitzer M, Hruby G, et al. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder. J Urol. 2014;192(3):696\u2013701. https:\/\/doi.org\/10.1016\/j.juro.2014.03.078.","journal-title":"J Urol"},{"issue":"4","key":"1657_CR47","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1200\/jco.1998.16.4.1298","volume":"16","author":"HW Herr","year":"1998","unstructured":"Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol. 1998;16(4):1298\u2013301. https:\/\/doi.org\/10.1200\/jco.1998.16.4.1298.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1657_CR48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3233\/blc-170134","volume":"3","author":"GW Moran","year":"2017","unstructured":"Moran GW, Li G, Robins DJ, Matulay JT, McKiernan JM, Anderson CB. Systematic review and Meta-Analysis on the efficacy of chemotherapy with transurethral resection of bladder tumors as definitive therapy for muscle invasive bladder Cancer. Bladder Cancer. 2017;3(4):245\u201358. https:\/\/doi.org\/10.3233\/blc-170134.","journal-title":"Bladder Cancer"},{"issue":"11","key":"1657_CR49","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023;29(11):2825\u201334. https:\/\/doi.org\/10.1038\/s41591-023-02568-1.","journal-title":"Nat Med"},{"key":"1657_CR50","doi-asserted-by":"publisher","unstructured":"Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F et al. Phase II trial of Risk-Enabled therapy after neoadjuvant chemotherapy for Muscle-Invasive bladder Cancer (RETAIN 1). J Clin Oncol.0(0):JCO\u201324. https:\/\/doi.org\/10.1200\/jco-24-01214","DOI":"10.1200\/jco-24-01214"},{"issue":"16suppl","key":"1657_CR51","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1200\/JCO.2024.42.16_suppl.4601","volume":"42","author":"R Li","year":"2024","unstructured":"Li R, Shah PH, Stewart TF, Bivalacqua T, Lamm DL, Geynisman DM, et al. Final results of CORE-001: A phase-2, single arm study of cretostimogene Grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ. J Clin Oncol. 2024;42(16suppl):4601. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4601.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1657_CR52","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","volume":"84","author":"PC Black","year":"2023","unstructured":"Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, et al. Phase 2 trial of Atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive High-risk Non-muscle-invasive bladder cancer: SWOG S1605. Eur Urol. 2023;84(6):536\u201344. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.004.","journal-title":"Eur Urol"},{"issue":"15suppl","key":"1657_CR53","doi-asserted-by":"publisher","first-page":"TPS4589","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4589","volume":"37","author":"M Roupret","year":"2019","unstructured":"Roupret M, Neuzillet Y, Bertaut A, Pignot G, Houede N, Champiat S, et al. ALBAN: an open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37). J Clin Oncol. 2019;37(15suppl):TPS4589\u2013TPS. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS4589.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1657_CR54","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/fon-2023-0271","volume":"20","author":"GD Steinberg","year":"2024","unstructured":"Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, et al. CREST: phase III study of Sasanlimab and Bacillus Calmette-Gu\u00e9rin for patients with Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024;20(14):891\u2013901. https:\/\/doi.org\/10.2217\/fon-2023-0271.","journal-title":"Future Oncol"},{"issue":"7suppl","key":"1657_CR55","doi-asserted-by":"publisher","first-page":"TPS500","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS500","volume":"37","author":"MD Santis","year":"2019","unstructured":"Santis MD, Abdrashitov R, Hegele A, Kolb M, Parker S, Redorta JP, et al. A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-gu\u00e9rin (BCG) versus BCG alone in high-risk, BCG-na\u00efve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC). J Clin Oncol. 2019;37(7suppl):TPS500\u2013TPS. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.TPS500.","journal-title":"J Clin Oncol"},{"issue":"4suppl","key":"1657_CR56","doi-asserted-by":"publisher","first-page":"TPS722","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS722","volume":"42","author":"ND Shore","year":"2024","unstructured":"Shore ND, Nishiyama H, Shariat SF, Steinberg G, Kamat AM, Alanee SR, et al. Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Gu\u00e9rin (BCG) with or without pembrolizumab for high-risk (HR) non\u2013muscle-invasive bladder cancer (NMIBC) that persists\/recurs after BCG induction. J Clin Oncol. 2024;42(4suppl):TPS722\u2013TPS. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.TPS722.","journal-title":"J Clin Oncol"},{"key":"1657_CR57","doi-asserted-by":"crossref","unstructured":"Van der Heijden M. ea. TAR-200 +\/- Cetrelimab and Cetrelimab Alone in Patients With Bacillus Calmette-Gu\u00e9rin\u2013Unresponsive High-Risk Non\u2013Muscle-Invasive Bladder Cancer: Updated Results From SunRISe-1. ESMO 2024. Spain2024.","DOI":"10.1016\/S2666-1683(24)01119-4"},{"issue":"9","key":"1657_CR58","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"T Mitin","year":"2013","unstructured":"Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14(9):863\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(13)70255-9.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1657_CR59","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023;24(6):669\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(23)00170-5.","journal-title":"Lancet Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01657-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:40:48Z","timestamp":1751607648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01657-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01657-3","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"26 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Parminder Singh (Disclosure Information): \u2022 Honoraria - Curio Science; Medpage\/ASCO \u2022 Consulting or Advisory Role - AVEO; Bayer; EMD Serono; ImmunityBio; Janssen Oncology; Seattle Genetics\/Astellas (Inst) \u2022Research Funding - EMD Serono (Inst) \u2022\tUncompensated Relationships - Seagen Mark Tyson \u2022 Consulting or Advisory Role: Urogen, Protara, Engene and Astra Zeneca Adri M. Durant, Swati PopliNo relationships to disclose. No financial or non-financial interests are directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}